Bank of America Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $126.00

Gilead Sciences (NASDAQ:GILD) had its price target lifted by equities research analysts at Bank of America from $116.00 to $126.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price target points to a potential upside of 9.12% from the stock’s previous close.

A number of other brokerages have also recently weighed in on GILD. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Wolfe Research began coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Oppenheimer boosted their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday. UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Finally, BMO Capital Markets upped their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.24.

Gilead Sciences Price Performance

GILD traded up $0.73 during trading on Wednesday, reaching $115.47. The stock had a trading volume of 5,076,848 shares, compared to its average volume of 7,707,052. The stock has a 50 day moving average of $98.28 and a two-hundred day moving average of $90.74. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $143.90 billion, a price-to-earnings ratio of 312.43, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $117.39.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 293,356 shares of company stock valued at $29,166,240 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently bought and sold shares of the stock. HHM Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC increased its position in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.